Statistics

Total Visits

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.65

Select a period of time:

Number of views in the range

Views
Weekly cabazitaxel in "unfit" metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial.15

Views

Views
December 20252
January 20260
February 20260
March 20262
April 20265
May 20260
June 20266
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States5
Argentina3
Colombia1
France1
Mexico1
Netherlands1
Panama1
Paraguay1
South Africa1
 

Top cities views

Views
Bogotá1
Casilda1
Cleveland1
Groningen1
Haedo1
Klerksdorp1
Los Tres Árboles1
Palm Coast1
Panama City1
Philadelphia1